[Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases].
Hansen
Per Boye
PB
Hillerød Sygehus, Medicinsk Afdeling F. peboha@fa.dk
Hasselbalch
Hans Carl
HC
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000276:immunology; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000276:immunology; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab